The EngenderHealth News Blog
EngenderHealth on YouTube EngenderHealth on Twitter EngenderHealth on FaceBook The latest news from and about EngenderHealth, a leading international nonprofit working in sexual and reproductive health. For more information, visit our web site or join us on YouTube, Facebook, and Twitter.
Showing posts with label aidsconference. Show all posts
Showing posts with label aidsconference. Show all posts

Friday, January 13, 2012

EngenderHealth on the Move

International conferences are always on our agenda. But this winter has been particularly busy so far, with staff attending the International Conference on Family Planning in Dakar, Senegal, and the International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA) in Addis Ababa, Ethiopia. Since our field staff cannot pack you in their suitcases and take you with them—they’re just not that strong!—we asked them to tell you a little about their experiences now that they are back home. 

 





2011 International Conference on Family Planning, Dakar: JAWEER BROWN (Technical Advisor, Family Planning)

What were some of your favorite moments from the conference, and why?

One of my personal highlights from the conference was a presentation by a young activist living with HIV. He really moved me and set the stage for my experience in Dakar. Against the backdrop of a large tent and competing with the rumblings of an enthusiastic audience, the activist reminded us of the human face behind the words family planning, HIV, systems strengthening, development, and all the jargon we use in our work. He represented the lives of so many we refer to as “client,” ”population,” or ”user.” With a palpable candor and passion, he pressed us to adhere to our commitments to make real change and embodied the purpose of our work: to meet the urgent sexual and reproductive health needs of young people like him.

Were there any takeaways from discussions surrounding the issue of HIV risk and hormonal injections?

Going into the conference, we knew the facts surrounding this important issue. An important takeaway that emerged on this topic, however, is the fact that we may never have conclusive evidence about a link between hormonal contraceptives and HIV risk. Strong leadership, therefore, is vital for proceeding within this uncertainty. This will involve investing more resources and attention to expand the contraceptive choices available to women and increase access to a wide method mix, including long-acting and permanent methods of family planning.

What other research highlights received special attention from conference participants?

I am a tech geek in disguise, and I really enjoyed a presentation on new contraceptive technologies. Two innovations in particular caught my eye: the microbicide/hormonal contraceptive ring, and the development of a topical gel contraceptive. 

What were some major contributions EngenderHealth made at the conference?

EngenderHealth contributed a great deal to the Implementing Best Practices (IBP) sessions, which were another major highlight of my experience in Dakar. The format of these sessions was unique.  Rather than Powerpoint presentations followed by a question-and-answer period, the sessions were broken up into roundtables, allowing for open dialogue in small groups of 8–10 people. It was a rare opportunity to sit down with colleagues and experts from around the world and take a bird’s eye view at what we do and how we do it.


2011 International Conference on AIDS and STIs in Africa, Addis Ababa: MARK BARONE (Senior Medical Associate)

What were some of your favorite moments from the conference, and why?

A favorite moment from the conference was a presentation that my colleague Dr. Quentin Awori delivered on our randomized controlled trial of the Shang Ring versus conventional male circumcision in Kenya and Zambia. Dr. Awori works in Homa Bay, Kenya, and is a co-investigator on the study. He is an up-and-coming young researcher, which made it even more gratifying to see our work presented by him. The presentation generated a lot of discussion and offered great hope that a device will simplify male circumcision and allow for more rapid scale-up.

I also particularly enjoyed the opportunity that the conference presented to connect with many of the people that I know who are working in the field of HIV and to meet new people. Conferences like this provide a venue to learn not only from the actual conference sessions, but also to talk with others and get a better sense of what is going on more broadly in the field  and to create opportunities for future collaborations.

What other research highlights received special attention from conference participants?

Voluntary medical male circumcision received a great deal of attention during ICASA, including a number of special sessions and many oral and poster presentations. I hope that emphasis on this proven HIV prevention intervention will spur along some of the programs in Sub-Saharan Africa that have been lagging a bit.

What work did EngenderHealth present, and how did it fit into the overall conference narrative and themes?

EngenderHealth was well represented at the conference, with oral and poster presentations that highlighted our work in voluntary medical male circumcision for HIV prevention, gender, and our work with most-at-risk populations (MARPs). We also had a booth in the exhibition area highlighting our HIV-related work, with a special focus on our work with MARPs in Ethiopia.

Tuesday, July 20, 2010

EngenderHealth joins the global health community in celebrating proof-of-concept of microbicides

At the International AIDS Conference in Vienna, there was standing ovation in a packed conference hall for the Caprisa 004 microbicide study. As the New York Times reports:

After two decades in which researchers searched fruitlessly for an effective vaginal microbicide to block H.I.V., South African scientists working in two AIDS-devastated communities of South Africa, one rural and one urban, say they have finally found something that shows real promise.

Women who used a vaginal microbicidal gel containing an antiretroviral medication widely used to treat AIDS, tenofovir, were 39 percent less likely over all to contract H.I.V. than those who used a placebo. Those who used the gel most regularly reduced their chances of infection 54 percent, according to a two-and-a-half year study of 889 women by Caprisa, a Durban-based AIDS research center.

Download the official press release (PDF, 168KB).

Wednesday, July 14, 2010

EngenderHealth at the International AIDS Conference: Highlights

PEPFAR Gender Symposium: Practical Approaches for Integration with HIV and AIDS, featuring Dunstan Bishanga of EngenderHealth’s CHAMPION Project, and new (as of 1 September 2010) EngenderHealth President Pamela W. Barnes

Sunday, July 18
Mini Room 8
, 1:30–3:30 pm


EngenderHealth co-launches the new Global HIV Stigma Reduction Network

Wednesday, July 21
Mini Room 3, 6:30–8:30 pm


Leadership & Accountability Development Workshop: Scaling Up Key Programmes to Protect Human Rights, led by Paul Perchal, Director, HIV and STI program, EngenderHealth

Monday, July 19
Mini Room 1, 2:30–6:00 pm


The Language of Love: Tanzanian Women Define Intimacy, Sexuality, and Violence in the 21st Century, M. Leslie-Rule, EngenderHealth CHAMPION Project

Wednesday, July 21
Session Room 9, 2:30–4:00 pm


EngenderHealth will be featured in more than 25 sessions at the International AIDS Conference. Download our complete schedule of activities (PDF, 376KB).

EngenderHealth at the International AIDS Conference 2010

Beginning on Sunday, July 18, policymakers, scientists, program experts, persons living with HIV, and others committed to ending the AIDS pandemic will gather in Vienna, Austria, for AIDS 2010, the 18th International AIDS Conference. Visit us at Booth #418!

Paul Perchal, director of EngenderHealth’s HIV/STI Program, will be among the conference participants. Paul’s commitment to this field is in part the legacy of losing two of his closest friends to AIDS during the mid-1990s. Gearing up for the conference, the theme of which is “Rights Here, Right Now,” Paul offers his perspective on the upcoming week in this brief Q&A:

As we head into the conference, what do you see as the most vital issues facing the field?
Universal access to prevention, care and treatment for people living with HIV and AIDS, regardless of where they live, remains paramount. The economic crisis means that donors are rethinking their priorities, and that some of the gains we’ve made in recent years could be undermined. There’s also renewed focus on human rights, and increased recognition that in places where HIV stigma persists, people just aren’t getting tested. Likewise, pregnant women are not accessing care and treatment to prevent transmitting the virus to their newborns. We really need more effective strategies to reduce stigma and its effects.

Male circumcision is also receiving wide attention. It has been proven to reduce the risk of HIV transmission in men by up to 60%, and many governments are now introducing large-scale programs to make the procedure widely available. In Kenya, for example, the government is rapidly expanding services so that 1.1 million men can opt for the procedure by 2015. While not a panacea, male circumcision is an essential tool for HIV prevention that is currently not available to millions of men who want it.

How will EngenderHealth be represented at the conference?
EngenderHealth’s expertise in reducing HIV-related stigma, engaging men to prevent HIV in their relationships and communities, and preventing mother-to-child transmission, along with what we’re learning in our large-scale male circumcision program in Kenya, will be showcased through special satellite sessions, oral presentations, and more than 20 posters. I’m especially excited that we’ll be sharing the results of our safety study of the Shang Ring, an innovative male circumcision device.

What are you most looking forward to?
The International AIDS Conference is always an opportunity to be part of the conversation about the direction the field is going in. It’s also inspiring to learn the latest in technical and clinical breakthroughs, and to engage with young and emerging leaders. Of course, it’s also great to catch up with colleagues. The opportunity for an exchange of ideas around our innovative work and for collective problem-solving is really incomparable.